Core Insights - Insight Molecular Diagnostics, Inc. (iMDx) aims to democratize access to molecular diagnostics, particularly in transplant monitoring, by developing self-run testing kits for hospitals [3][4][7] - The company recently rebranded from Oncocyte to Insight Molecular Diagnostics to better reflect its mission [4][8] - iMDx's first commercial focus is on measuring donor-derived cell-free DNA to monitor transplanted organ health [4][5] Company Strategy - iMDx is working on a regulatory pathway to obtain FDA clearance for its diagnostic tests, with a submission expected by the end of 2025 and potential clearance in 2026 [6] - The company has a research-use-only version of its kit currently utilized by 10 centers globally [5] - iMDx's strategy includes increasing visibility with investors as it approaches key regulatory milestones [6] Market Position - The company has relocated its headquarters from Irvine, California, to Nashville, Tennessee, and changed its NASDAQ symbol effective June 18, 2025 [8] - iMDx's mission is to improve patient outcomes by making advanced molecular diagnostic testing more accessible [4][7]